Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease

R.C. Melchers*, R. Willemze, J.S.P. Vermaat, P.M. Jansen, L.A. Daniels, H. Putter, M.W. Bekkenk, E.R.M. de Haas, B. Horvath, M.M. van Rossum, C.J.G. Sanders, J.C.J.M. Veraart, M.H. Vermeer, K.D. Quint

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

4 Citations (Web of Science)
Original languageEnglish
Pages (from-to)769-773
Number of pages6
JournalBlood
Volume135
Issue number10
DOIs
Publication statusPublished - 5 Mar 2020

Keywords

  • brentuximab vedotin
  • classification
  • diagnosis
  • eortc
  • guidelines
  • iscl
  • large-cell lymphoma
  • papulosis
  • DIAGNOSIS
  • PAPULOSIS
  • EORTC
  • GUIDELINES
  • BRENTUXIMAB VEDOTIN
  • CLASSIFICATION
  • LARGE-CELL LYMPHOMA
  • ISCL

Cite this